08/15/2024
7:00 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/13/2024
7:01 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/13/2024
7:05 AM | UroGen Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/08/2024
3:30 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/08/2024
8:06 AM | BUTITTA CYNTHIA M (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:07 AM | UroGen Pharma (Issuer)
WEN LEANA (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:08 AM | Robinson James A. Jr. (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
08/08/2024
8:09 AM | Holden Stuart (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:10 AM | UroGen Pharma (Issuer)
Wildman Daniel George (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:11 AM | Cohen Fred E (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:11 AM | Belldegrun Arie (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/09/2024
4:30 PM | UroGen Pharma (Filer)
| Form ARS | |
06/24/2024
4:25 PM | COWEN AND COMPANY, LLC (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
06/24/2024
3:51 PM | Point72 Asset Management, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
06/18/2024
4:07 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/13/2024
9:51 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/11/2024
12:15 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/11/2024
5:16 AM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024
7:01 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/13/2024
7:05 AM | UroGen Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/08/2024
1:22 PM | BlackRock Inc. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
04/29/2024
7:18 AM | UroGen Pharma (Filer)
| Form 10-K/A | |
03/20/2024
3:38 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2024
12:48 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/14/2024
7:16 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/14/2024
7:17 AM | UroGen Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/04/2024
6:00 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/01/2024
6:00 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/22/2024
8:23 AM | Arkin Moshe (Filed by)
UroGen Pharma (Subject)
| Form SC 13D/A | |
02/14/2024
6:07 AM | RTW INVESTMENTS, LP (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
02/12/2024
4:47 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/12/2024
4:43 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/07/2024
3:15 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/05/2024
8:15 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/05/2024
8:16 PM | Smith Jason Drew (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/02/2024
6:04 PM | Barrett Elizabeth A. (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
6:05 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
6:07 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
6:12 PM | Smith Jason Drew (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
1:18 PM | BlackRock Inc. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
02/01/2024
9:13 AM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
The death of Nvidia? (Ad) Today, I’m warning of another looming catastrophe.
Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out.
You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy...
There's also no escaping that The Big AI Die-Up is coming. So go here now to read my new report The Big AI Die-Up… while you still can. |
02/01/2024
8:53 AM | Smith Jason Drew (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2024
3:16 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/02/2024
7:04 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/29/2023
3:30 PM | RA CAPITAL MANAGEMENT, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
11/14/2023
3:20 PM | UroGen Pharma (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
09/17/2023
11:15 PM | UroGen Pharma (Filer)
| Form EFFECT | |
09/15/2023
12:39 PM | GREAT POINT PARTNERS LLC (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
09/11/2023
3:15 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/08/2023
3:16 PM | UroGen Pharma (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
09/08/2023
2:40 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/08/2023
2:41 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/08/2023
2:41 PM | Smith Jason Drew (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/08/2023
2:41 PM | UroGen Pharma (Issuer)
WEN LEANA (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/08/2023
2:41 PM | Robinson James A. Jr. (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/08/2023
2:42 PM | Holden Stuart (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/08/2023
2:42 PM | UroGen Pharma (Issuer)
Wildman Daniel George (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/08/2023
2:42 PM | Cohen Fred E (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/08/2023
2:43 PM | BUTITTA CYNTHIA M (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/08/2023
2:43 PM | Belldegrun Arie (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
